Cytodyn Inc (CYDY)

[Borel Fields]

NEJM more impactful on trials than patient testimony

The New England Journal of Medicine article will be far more impactful in filling trials than the patient’s video testimony, no matter how compelling she was.

Any doctor who reads the NEJM article (and nearly all COVID-practitioners will by Monday) will now consider leronlimab a legitimate possibility for the treatment arsenal. That wasn’t true yesterday.

Consider their (Montefiore’s) analysis of a subset of 28 of the 36 consecutive “severely ill” kidney transplant patients:

• 24 of 28 were administered hydroxychloroquine, along with another drug where d-dimer levels suggested it. Severely ill, indeed.
• 2 of 28 were administered tocilizuman (Actemra), a interleukin-6 inhibitor. There was no comment on their outcomes.
• 6 of 28 were administered leronlimab. There were about 80 words, along with a table, describing their outcomes. Presumably these are the patients NP previously mentioned.
• All presented with extremely high interleukin-6 levels, all of which “decreased markedly” by day 3. “However,” this improvement “only” prevented 1 of the 6 from being intubated. Is that a walk-back from NP’s comments? There were no remarks on survival.

I’ll take the “howevers” on this patient base. All-in-all, many more MDs will now be open to being involved in leronlimab trials.